KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Debt: 2018-2024

Historic Total Debt for Castle Biosciences (CSTL) over the last 3 years, with Dec 2024 value amounting to $10.0 million.

  • Castle Biosciences' Total Debt rose 0.34% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $10.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Total Debt is $10.0 million, which was down 60.10% from $25.1 million recorded in FY2019.
  • Castle Biosciences' 5-year Total Debt high stood at $10.0 million for FY2024, and its period low was $10.0 million during FY2024.
  • Over the past 1 years, Castle Biosciences' median Total Debt value was $10.0 million (recorded in 2024), while the average stood at $10.0 million.